Repotrectinib in patients with ROS1 fusion-positive (ROS1+) NSCLC: Update from the pivotal phase 1/2 TRIDENT-1 trial Meeting Abstract
| Authors: | Drilon, A.; Camidge, D. R.; Lin, J. J.; Kim, S. W.; Solomon, B.; Dziadziuszko, R.; Besse, B.; Goto, K.; de Langen, A. J.; Wolf, J.; Lee, K. H.; Popat, S.; Springfeld, C.; Nagasaka, M.; Felip, E.; Yang, N.; Lu, S.; Kao, S.; Velcheti, V.; Cheema, P.; Stopatschinskaja, S.; Mehta, M.; Trone, D.; Ades, F.; Calvet, C. Y.; Cho, B. C. |
| Abstract Title: | Repotrectinib in patients with ROS1 fusion-positive (ROS1+) NSCLC: Update from the pivotal phase 1/2 TRIDENT-1 trial |
| Meeting Title: | 2023 North America Conference on Lung Cancer |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 19 |
| Issue: | 7 Suppl. |
| Meeting Dates: | 2023 Dec 1-3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-07-01 |
| Start Page: | e4 |
| End Page: | e5 |
| Language: | English |
| ACCESSION: | WOS:001277064200007 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2024.05.150 |
| Notes: | Meeting Abstract: PPD01.02 -- Source: Wos |
